Completion of Neu2000 clinical phase I study in the U.S

M & A with Pengen co. (current. Biopharma Dividison)

M&A with EOLITH Co. (a Kosdaq listed company)
National R&D Project Award from the Ministry of Health & Welfare
    : Development of AAD-2004 as an Anti-Alzheimer's Drug
Frontier Project Award from the Ministry of Science & Technology
    : Development of NP-07 for pain
Initiation of Neu2000 clinical phase I study in the U.S.

National R&D project, AAD-2004 (Ministry of Health & Welfare)
Completion of efficacy study in spinal code injury, Neu2000

Establishment of US Subsidiary, AmKor Pharma (Seattle, WA)
Development of new drug candidate, AAD-2004
    : Anti-Alzheimer's Drug
Validation through efficacy studies in Glaucoma, Neu2000
Awarded the Driving Force Project for the Next Generation from Gyeonggi Provincial Government
    : Development of a New Drug in spinal cord injury and ALS

Initiation of Neu2000 pre-clinical studies in the U.S.
21 C Frontier Project Award from the Ministry of Science & Technology
    : Development for an Anti-Alzheimer's Drug

Out-license of Neu2000 for Korea : Choongwae Pharma

Completion of efficacy study in stroke, Neu2000
National Lab Acknowledgement (Korea Industrial Technology Association

Development of new drug candidate, Neu2000

Venture Business Acknowledgement (Small and Medium Business Administration)

Establishment of GNT Pharma
G7 Project Award from the Ministry of Science & Technology
    : Development of Alzheimers Disease models and Neuroprotectant compounds